TCGA-44-A47B-01A-11R-A24H-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.400
- ANGIOGENESIS+0.180
- PROTEIN_SECRETION+0.180
- UV_RESPONSE_DN+0.160
- HEME_METABOLISM+0.150
- TNFA_SIGNALING_VIA_NFKB+0.130
- ANDROGEN_RESPONSE+0.120
- PI3K_AKT_MTOR_SIGNALING+0.120
- CHOLESTEROL_HOMEOSTASIS+0.100
- PANCREAS_BETA_CELLS+0.090
Top 10 suppressed
- MYC_TARGETS_V2-0.520
- E2F_TARGETS-0.400
- MTORC1_SIGNALING-0.320
- OXIDATIVE_PHOSPHORYLATION-0.310
- MYC_TARGETS_V1-0.290
- G2M_CHECKPOINT-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.250
- APICAL_SURFACE-0.240
- GLYCOLYSIS-0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-7938-01A-11R-2170-07 | — | cohortA1 | 0.753 |
| 2 | AUR-AFUM-TTP1-A-1-0-R-A741-41 | — | D | 0.752 |
| 3 | AUR-AFE4-TTP1-A-1-0-R-A741-41 | — | D | 0.751 |
| 4 | AUR-AER4-TTP1-A-1-0-R-A741-41 | — | D | 0.747 |
| 5 | AUR-AER8-TTP1-A-1-0-R-A741-41 | — | D | 0.731 |
| 6 | SRR12475139 | — | — | 0.723 |
| 7 | TCGA-97-7546-01A-11R-2039-07 | — | cohortA1 | 0.723 |
| 8 | TCGA-AO-A0JG-01A-31R-A084-07 | — | A | 0.715 |
| 9 | TCGA-BH-A1EU-01A-11R-A137-07 | — | A | 0.714 |
| 10 | R347 | — | — | 0.711 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.020 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.020 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |